StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
194A.T$1235.00-5.78%
Fair $1235.00+0.0%

194A.T

194A.T

Healthcare / Medical Care FacilitiesTokyo

$1235.00

-77.00 (-5.78%)

Fairly Valued+0.0%Fair Value $1235.00Fund rank 25/100 · Data gapFallback financials|
SA 39/D
F-Score: 6/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 17%

FCF escenarios

weak_data · normalized FCF $411.9M · quality 33.3/100

Data gap 25/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 29/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

39/100

D

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

12/100

SEC 0%

Latest source: unknownPeriods: 3Warnings: 0unknown: 3
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 194A.TLocal privado en este navegador · 194A.T
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$9.3B

P/E

13.1x

↓

EV/EBITDA

9.8x

↓

ROE

26.4%

↑

Gross Margin

27.5%

↓

Debt/Equity

1.42

↑
52-Week Range$1235
$686$2900

TradingView lightweight chart

194A.T price, volumen y niveles de valoración

Último $1,255Periodo +53.6%
Fair value: $1,235

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2024 · 2 años de histórico normalizado

Revenue CAGR

+7.8%

FCF CAGR

—

FCF margin

8.3%

FCF / Net income

0.74x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $4.99B · net income $558.4M · FCF $411.9M

2022-FY → 2024-FY

Gross margin

27.5%-0.9% pts

Operating margin

16.6%-0.2% pts

Net margin

11.2%+3.8% pts

FCF margin

8.3%+33.0% pts
MetricTTM
2024
2023
2022
Income Statement
Revenue$4.99B$4.99B$4.65B$4.30B
Net Income$558.4M$558.4M$506.1M$316.9M
EBITDA$1.16B$1.16B$1.13B$865.6M
EPS——68.1742.40
Gross Margin27.5%27.5%27.6%28.4%
Operating Margin16.6%16.6%17.3%16.8%
Net Margin11.2%11.2%10.9%7.4%
Balance Sheet
Debt/Equity1.421.422.123.14
Current Ratio1.271.27——
Cash Flow
Free Cash Flow$411.9M$411.9M$458.6M$-1.06B
Returns
ROE26.4%26.4%33.3%31.3%
Valuation
P/E13.1213.12——
EV/EBITDA9.769.76——
P/B4.374.37——
Growth & Yield
Revenue Growth7.3%7.3%8.3%—
EPS Growth——60.8%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +75.5%

Total return

+75.5%

Start / end P/E

n/dx → n/dx

EPS bridge

68.17 → n/d

Residual

+75.5%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term+75.5%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.